Table 1.
List of current and potential BAFF antagonists
| Blocks BAFF | |||||
| Therapeutic agent | Soluble | Membrane | Blocks APRIL | Current status | Reference |
| LymphoStat-B (Human Genome Sciences) | + | - | - | Phase II clinical trialsa | [38] |
| BAFF-R-Ig (Biogen Idec) | + | + | - | In development | [39] |
| TACI-Ig (ZymoGenetics Serono) | + | + | + | Phase I clinical trials | [28] |
| BCMA-Ig | +b | +/- | + | - | [39] |
| Mutated BCMA-Ig | - | - | + | - | [40] |
| MiniBR3 (BAFF-R) | + | + | - | Pre-clinical | [37] |
| Peptidomimetics of: | |||||
| BAFF-R | + | + | - | Pre-clinical | [37] |
| TACI | + | + | + | Hypothetical | [37] |
| BCMA | + | + | + | Hypothetical | [37] |
aSystemic lupus erythematosus and rheumatoid arthritis. bLow affinity for BAFF. BAFF-R, BAFF receptor; BCMA, B cell maturation antigen; TACI, transmembrane activator and calcium modulator ligand interactor.